Product pipeline
We have biosimilars products continuously under development to help improve healthcare accessibility worldwide.
What are biosimilars?
Biosimilars have no clinical differentiation from existing, approved biologics, with equivalent efficacy and safety.
The development and manufacture of biosimilars is a complex and challenging process. We have invested in our biosimilar capabilities with our advanced pipeline and EnzeneXTM continuous bioprocess manufacturing, allowing us to develop, manufacture and launch a range of biosimilar products.
Demand for biosimilars is increasing because of:
- Patent expirations: Blockbuster biologics patents are expiring, paving the way for biosimilar manufacturers to develop and commercialize products
- Cost-effectiveness: Biosimilars offer a more affordable alternative to biologics while maintaining comparable efficacy and safety
- Technological advancements: Biotechnology advancements are enabling the development of biosimilars that are highly similar to their originator products
- Regulatory support: Regulatory agencies worldwide are supporting the development and approval of biosimilars
Our biosimilars product portfolio is continuously under development with molecules from pre-clinical to late stages.
Global Pipeline
| Pipeline | Global | Therapy Area | 2024 Global Sales ($, Billions) |
Patent Expiry/ LOE |
| Priority I: Strategic Priority Assets Key Focus for Immediate Development | DUPILUMAB (Atopic Dermatitis)
OCRELIZUMAB (Multiple Sclerosis) RISANKIZUMAB (Plaque Ps, PsA) EMICIZUMAB (O) (Hemophilia A) |
Auto-immune (Inflammatory)
Neurology Auto-immune (Inflammatory) Orphan (Hematology) |
15.6
7.8 12.9 4.6 |
2031 (US); 2032 (EU)
2029 (US); 2028 (EU) 2033 (US); 2034 (EU) 2032 (US); 2033 (EU) |
| Priority II: Flexible High Potential Assets Standby – Capacity, Strategy, Mkt Conditions | BENRALIZUMAB (Asthma)
MEPOLIZUMAB (Asthma) BELIMUMAB (O) (SLE) DULAGLUTIDE (Type II Diabetes) |
Auto-immune (Respiratory)
Auto-immune (Respiratory) Auto-immune (Immunology) Metabolic Disorders |
2.0
2.5 1.8 5.3 |
2029 (US); 2028 (EU)
2027 (US); 2025 (EU) 2025 (US); 2026 (EU) 2027 (US); 2029 (EU) |
(O): Orphan
Domestic Pipeline
| Pipeline | Domestic (India) |
| CDMO (Signed with Partner) |
NIVOLUMAB (Oncology)**
PEMBROLIZUMAB (Oncology)** |
| Priority I (Strategic Priority Assets)Key Focus for Immediate Development |
BENRALIZUMAB (Respiratory)
ROMOSOZUMAB (Osteoporosis) |
| Priority II (Flexible High Potential Assets)Standby – Capacity, Strategy, Mkt Conditions |
EVOLOCUMAB
(Hyperlipidemia) DULAGLUTIDE (Type II Diabetes) |
** Signed with a Partner for India; Alternative high titer clones and process available for partnership for Global
Enzene is actively engaged in the development of additional biosimilars with various partners, either as a CDMO or a co-development partner.
Partners we work with
Biomm
Centurion
IDD biotech
Ipca
Lupin
Mankind pharma
Pharmasyntez
Shin Poong Pharm
SSB-Sartorius
Theramex
Start your biosimilars journey
Interested in our biosimilar development pipeline? Reach out to find out more about how Enzene can help deliver trusted and affordable medicines at speed.